Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market. While Alvotech highlighted successful product ...

Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...

Pharmerging Market Pharmerging Market Poised for Rapid Growth Amid Rising Healthcare Demands US, NY, UNITED STATES, March 15, 2025 /EIN ...

India has a strong pharma network, with more than 10,000 manufacturing facilities, over 3,000 pharma companies.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...